AN2 Therapeutics, Inc.
ANTXAs of the close on Sep 25, 2026
Price
$4.88
Market cap
—
The cover-page share count does not match the latest report's share count
P/E (diluted TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
EPS (TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How AN2 Therapeutics, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 5 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 2, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among AN2 Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-05-30 · Leonard Braden Michael: Larger than 68 of the 70 other insider sales of Common Stock on file. SEC filing
- 2025-05-28 · Leonard Braden Michael: Larger than 69 of the 70 other insider sales of Common Stock on file. SEC filing
- 2025-05-28 · Leonard Braden Michael: Larger than 64 of the 70 other insider sales of Common Stock on file. SEC filing
- 2025-05-28 · Leonard Braden Michael: Larger than 67 of the 70 other insider sales of Common Stock on file. SEC filing
- 2024-08-14 · Leonard Braden Michael: Larger than 17 of the 18 other insider purchases of Common Stock on file. SEC filing
- 2024-08-09 · RA Capital Healthcare Fund LP: Larger than 66 of the 70 other insider sales of Common Stock on file. SEC filing
- 2024-08-09 · RA Capital Healthcare Fund LP: Larger than all 70 other insider sales of Common Stock on file. SEC filing
- 2024-01-18 · Zakrzewski Joseph S: Larger than 64 of the 70 other insider sales of Common Stock on file. SEC filing
- 2023-08-18 · RA Capital Healthcare Fund LP: Larger than all 18 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2025-05-28–2025-06-02: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2024-11-20–2024-11-27: 5 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing )
- 2024-11-19–2024-11-26: 6 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing )
- 2024-11-18–2024-11-20: 7 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-29 | Williams Sarah Joanne · Principal Accounting Officer | Common Stock | S — Open market or private sale | −265 | 4.43 | SEC filing |
| 2026-03-03 | Williams Sarah Joanne · Principal Accounting Officer | Common Stock | S — Open market or private sale | −327 | 1.06 | SEC filing |
| 2026-01-06 | Day Lucy · Chief Financial Officer | Common Stock | S — Open market or private sale | −5,512 | 1.01 | SEC filing |
| 2026-01-06 | Prior Stephen David · Chief Strategy Officer | Common Stock | S — Open market or private sale | −2,858 | 1.01 | SEC filing |
| 2026-01-06 | Chanda Sanjay · Chief Development Officer | Common Stock | S — Open market or private sale | −5,956 | 1.01 | SEC filing |
| 2026-01-06 | Eizen Joshua M · See Remarks | Common Stock | S — Open market or private sale | −6,931 | 1.01 | SEC filing |
| 2026-01-05 | Day Lucy · Chief Financial Officer | Common Stock | S — Open market or private sale | −3,295 | 1.00 | SEC filing |
| 2026-01-05 | Eizen Joshua M · See Remarks | Common Stock | S — Open market or private sale | −17,923 | 1.00 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-04-10 | Aziz Kabeer · Director | Common Stock | A — Grant, award, or other acquisition | +3,775 | SEC filing |
| 2026-04-10 | Marks Gilbert Lynn · Director | Common Stock | A — Grant, award, or other acquisition | +3,775 | SEC filing |
| 2026-04-10 | Martin Patricia A. · Director | Common Stock | A — Grant, award, or other acquisition | +1,192 | SEC filing |
| 2026-03-19 | Easom Eric · Chief Executive Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +225,000 | SEC filing |
| 2026-03-19 | Marks Gilbert Lynn · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +10,665 | SEC filing |
| 2026-03-19 | FitzPatrick Margaret M · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +11,463 | SEC filing |
| 2026-03-19 | Zakrzewski Joseph S · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +10,362 | SEC filing |
| 2026-03-19 | Zakrzewski Joseph S · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +99,999 | SEC filing |
Showing 8 of 16 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-03-19 | Chanda Sanjay · Chief Development Officer | Stock Option (right to buy) | D — Disposition to the issuer | −66,000 | SEC filing |
| 2026-03-19 | FitzPatrick Margaret M · Director | Stock Option (right to buy) | D — Disposition to the issuer | −10,362 | SEC filing |
| 2026-03-19 | Readnour Robin Shane · Director | Stock Option (right to buy) | D — Disposition to the issuer | −20,724 | SEC filing |
| 2026-03-19 | Martin Patricia A. · Director | Stock Option (right to buy) | D — Disposition to the issuer | −23,742 | SEC filing |
| 2026-03-19 | Marks Gilbert Lynn · Director | Stock Option (right to buy) | D — Disposition to the issuer | −10,362 | SEC filing |
| 2026-03-19 | FitzPatrick Margaret M · Director | Stock Option (right to buy) | D — Disposition to the issuer | −11,463 | SEC filing |
| 2026-03-19 | Spigelman Melvin K · Director | Stock Option (right to buy) | D — Disposition to the issuer | −16,941 | SEC filing |
| 2026-03-19 | Spigelman Melvin K · Director | Stock Option (right to buy) | D — Disposition to the issuer | −10,362 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.